Guillain-Barré syndrome following influenza vaccination

JAMA

Volumn 292, Issue 20, 2004, Pages 2478-2481

  Haber, Penina ^a   DeStefano, Frank ^a   Angulo, Fredrick J ^b   Iskander, John ^a   Shadomy, Sean V ^a   Weintraub, Eric ^a   Chen, Robert T ^a  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGED; ARTICLE; FOLLOW UP; GUILLAIN BARRE SYNDROME; HEALTH SURVEY; HUMAN; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; SWINE INFLUENZA VIRUS;

EID: 9244233324     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.20.2478     Document Type: Article

References (27)

1. Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome, J Infect Dis. 1997; 176(suppl 2):S92-S98.
2. Schonberger LB, Bergman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol. 1979;110: 105-123.
3. Centers for Disease Control and Prevention. Guillain-Barré syndrome-United States. MMWR Morb Mortal Wkly Rep. 1976;25:401.
4. Langmuir AD, Bregman DJ, Kurland LT, Nathanson N, Victor M. An epidemiologic and clinical evaluation of Guillain-Barré Syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol. 1984;119:841-879.
5. Breman JG, Hayner NS. Guillain-Barré syndrome and its relationship to swine influenza vaccination in Michigan, 1976-1977. Am J Epidemiol. 1984;119:880-889.
6. Marks JS, Halpin TJ. Guillain-Barré Syndrome in recipients of A/New Jersey influenza vaccine. JAMA. 1980)243:2490-2494.
7. Safranek TJ, Lawrence DN, Kurland LT, et al. Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccination 1976-1977: results of two-states study. Am J Epidemiol. 1991;133:940-951.
8. Institute of Medicine. Immunization Safety Review: Influenza Vaccines and Neurological Complications. Washington, DC: National Academy Press; 2003.
9. Hurwitz ES, Schonberger LB, Nelson DB, Holman RC. Guillain-Barré syndrome and the 1978-1979 influenza vaccine. N Engl J Med. 1981;304:1557-1561.
10. Kaplan JE, Katona P, Hurwitz ES, Schonberger LB. Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981: lack of an association with influenza vaccination. JAMA. 1982;248:698-700.
11. Roscelli JD, Bass JW, Pang L. Guillain-Barré syndrome and influenza vaccination in the US Army, 1980-1988. Am J Epidemiol. 1991;133:952-955.
12. Chen RT, Kent J, Rhodes P, Simon P, Schonberger L. Investigation of a possible association between influenza vaccination and Guillain-Barré syndrome in the United States, 1990-91 [abstract]. Post Mark Surveill. 1992;6:5-6.
13. Lasky T, Terracciano GJ, Magder L, et al, The Guillain-Barré syndrome and the 1992-93 and 1993-94 influenza vaccines. N Engl J Med. 1998;339:1797-1802.
14. Chen RT, Rastogi SC, Mullen JR. The Vaccine Adverse Event Reporting System (VAERS). Vaccine. 1994; 12:542-550.
15. Singleton JA, Lloyd JC, Mootrey GT, et al. An overview of the Vaccine Adverse Event Reporting System (VAERS) as a surveillance system. Vaccine. 1999;17: 2908-2917.
16. Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. MMWR Morb Mortal Wkly Rep. 2003;52SS-1:1-24.
17. Ellenberg SS, Chen R. The complicated task of monitoring vaccine safety. Public Health Rep. 1997; 112:10-21.
18. Massey JT, Moore TF, Parsons VL, Tadros W. National Health Interview Survey, 1985-1934: Design and Estimation. Hyattsville, Md: Public Health Service; 1989. DHHS Publication 89-1384. Vital and Health Statistics, Series 2: Data Evaluation and Methods Research, No. 110.
19. United States Government Census Report. 2002. Available at: http://www.census.gov. Accessed October 6, 2003.
20. Steiner C, Elixhauser E, Schnaier J. The Healthcare Cost and Utilization Project: an overview. Eff Clin Pract. 2002;5:143-151.
21. O'Mara D, Fukuda K, Singleton JA. Influenza vaccine: ensuring timely and adequate supplies. Infect Med. 2003;20:548-554.
22. Teutsch SM, Churchill RE, eds. Principles and Practice of Public Health Surveillance. 2nd ed. New York, NY: Oxford University Press; 2000.
23. Rosenthal S, Chen RT, The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health. 1995;85:1706-1709.
24. Varricchio F, Iskander J, Destefano F, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J. 2004;23:287-294.
25. Rees JH, Soudain SE, Gregson NA, Hughes RAC. Campylobactor jejuni infection and Guillain-Barré syndrome. N Engl J Med. 1995;333:1374-1379.
26. Mishu B, Blaser MJ. Role of infection due to Campylobactor jejuni in the initiation of Guillain-Barré syndrome. Clin Infect Dis. 1993;17:104-107.
27. Centers for Disease Control and Prevention. Preliminary FoodNet data on the incidence of food borne illness: selected sites, United States, 2003. MMWR Morb Mortal Wkly Rep. 2004;53:338-343.